Home

GREGORY T SCHIFFMAN

CIK 1239011 · Chief Financial Officer · last filed 2026-06-18

GREGORY T SCHIFFMAN is a Chief Financial Officer who has filed 92 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for FABC, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$562.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.93M

Companies

8

Total Filings

92

Lifetime Open-Market Net

-$562.9K

Filer Profile

Reported Address
1030 NW JOHNSON ST
UNIT 608
PORTLAND, OR 97209
Formerly Known As
SCHIFFMAN GREOGRY T (2004–2004)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FABC Director — $2.41 — $0 1 2026-06-18
StableX Technologies, Inc. (SBLX) Delisted Director — $3.10 — $0 1 2025-10-31
StableX Technologies, Inc. (AYRO) Delisted Director 6,712 $7.08 $47.5K -$177.2K 14 2024-12-02
ABSI Chief Financial Officer 605,165 $9.74 $5.89M $0 3 2023-03-03
StableX Technologies, Inc. (DCAR) Delisted Director 6,329 — — $0 2 2019-08-29
IOVANCE BIOTHERAPEUTICS, INC. (LBIO) Delisted Chief Financial Officer — — — $0 1 2016-11-15
STEM Chief Financial Officer 9,007 $4.48 $40.4K $49.8K 7 2016-04-18
VNUS MEDICAL TECHNOLOGIES INC (VNUS) Delisted Director 5,000 — — -$435.6K 12 2009-06-17

Recent Filings

92 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 FABC Grant (A) — $0 EDGAR
2025-10-31 StableX Technologies, Inc. (SBLX) Delisted Grant (A) — $0 EDGAR
2024-12-02 StableX Technologies, Inc. (AYRO) Delisted Mixed +79,868 $0 EDGAR
2023-08-03 StableX Technologies, Inc. (AYRO) Delisted Sell (S) −7,274 -$5.9K EDGAR
2023-08-01 StableX Technologies, Inc. (SBLX) Delisted Notice (144) −7,274 -$5.9K EDGAR
2023-05-05 StableX Technologies, Inc. (AYRO) Delisted Sell (S) −6,810 -$3.3K EDGAR
2023-05-03 StableX Technologies, Inc. (SBLX) Delisted Notice (144) −6,810 -$3.3K EDGAR
2023-03-03 ABSI Grant (A) — $0 EDGAR
2023-02-03 StableX Technologies, Inc. (AYRO) Delisted Mixed +108,573 -$2.9K EDGAR
2022-12-21 — Mixed +36,167 $0
Showing 1–10 of 92
Page 1 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.